NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement equity grants for five non-executive new hires on May 1, 2026.

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement equity grants for five non-executive new hires on May 1, 2026. The Compensation Committee approved 50,400 share options (exercise price $28.43) and 15,400 restricted stock units.

Options vest over four years (25% at one year then 36 monthly installments). RSUs vest over three years (one-third each year). Grants issued under the 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

Argus May 4 session

+5.03% close to close Open Argus

Details

News Market Reaction – NAMS

In the May 4 session, NAMS gained 5.03%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.0% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +5.0% in the session following this news. A strong positive reaction aligns with prior responses to similar equity grant announcements, which previously accompanied 3–4% moves on routine inducement news. While the awards add incremental share-based compensation over time, they also reflect ongoing hiring to support late-stage programs. Investors would watch how repeated equity incentives, insider selling activity, and conference or clinical updates interact to determine whether enthusiasm proves durable.

Key Figures

Inducement stock options: 50,400 shares Option exercise price: $28.43 per share Option vesting term: 4 years +5 more

Inducement stock options

50,400 shares

Aggregate options granted to five non-executive hires under 2024 Inducement Plan

Option exercise price

$28.43 per share

Exercise price equals Nasdaq closing price on May 1, 2026 (grant date)

Option vesting term

4 years

25% after one year, remainder in 36 equal monthly installments

Inducement RSUs

15,400 shares

Aggregate restricted stock units granted to five non-executive new hires

RSU vesting term

3 years

One-third vesting on each of the first three anniversaries of vesting start

ESPP share reserve

1,150,000 shares

Shares reserved under proposed 2026 Employee Stock Purchase Plan in PRE 14A

Short interest

7.93%

Reported short interest as percentage of float

Days to cover

8.74 days

Short interest relative to recent trading volume

Historical Context

5 past events · Latest: Apr 08

5 events

1. Apr 08

   Conference appearance

   24h Move

   +0.3%

   Needham virtual healthcare conference fireside chat announcement and webcast details.

2. Apr 02

   Inducement grants

   24h Move

   +3.4%

   Inducement options and RSUs for two non-executive hires under 2024 plan.

3. Mar 23

   Scientific presentations

   24h Move

   +3.7%

   ACC.26 posters on obicetrapib kidney outcomes, safety, and LDL-CVD risk data.

4. Mar 06

   Inducement grants

   24h Move

   +3.0%

   Equity inducement awards to two hires with multi-year vesting schedules.

5. Feb 25

   Investor conferences

   24h Move

   -2.8%

   Planned participation in multiple March investor conferences and webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved the grant of inducement share options... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"The Compensation Committee... also approved the grant of restricted stock units covering an aggregate of 15,400 of NewAmsterdam’s ordinary shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $28.43, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on May 1, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 15,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units were granted on May 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity inducement did NewAmsterdam (NAMS) grant on May 1, 2026?

NewAmsterdam granted 50,400 share options and 15,400 restricted stock units on May 1, 2026. According to NewAmsterdam, the awards were inducements for five non-executive new hires under the 2024 Inducement Plan and Nasdaq Rule 5635(c)(4).

What is the exercise price for NAMS share options granted May 1, 2026?

The exercise price for the options is $28.43 per share, equal to the closing market price on the grant date. According to NewAmsterdam, that price reflects the Nasdaq closing price on May 1, 2026 used for the grant.

How do the NAMS option vesting terms work for the May 1, 2026 grants?

Options vest over four years with 25% at the one-year anniversary and the remainder in 36 equal monthly installments. According to NewAmsterdam, vesting is subject to each employee's continued service on vesting dates.

What are the vesting terms for the restricted stock units NewAmsterdam granted on May 1, 2026?

The restricted stock units vest over three years, with one-third vesting at each annual anniversary. According to NewAmsterdam, vesting is conditioned on the employee's continued service through each vesting date.

Under which plan and Nasdaq rule were the NAMS inducement awards made?

The awards were granted under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). According to NewAmsterdam, the grants were approved by the Compensation Committee as inducements for new hires.